EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical efficacy and potential biomarkers of response to upadacitinib therapy in patients with severe atopic dermatitis and comorbidities

Evgeniy V. Smolnikov, Maria G. Byazrova, Alla O. Litovkina, Olga G. Elisyutina, Elena S. Fedenko

Russian Journal of Allergy · 28.04.2026 · 23 (2) · 247-257

DOI: 10.36691/rja17090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Allergy, online erschienen am 28.04.2026. Verfasst von Evgeniy V. Smolnikov und 4 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is a chronic multifactorial inflammatory skin disease characterized by pruritus, a relapsing course, and characteristic morphological and topographical features that develops in genetically predisposed individuals against the background of a T2-immune response. Cytokines from T helper 2 and type 2 innate lymphoid cells — interleukins 4, 13, and 31 — play a key role in the pathogenesis of the disease, activating the JAK/STAT signaling pathways (primarily JAK1/STAT6). Despite the proven efficacy of selective Janus kinase inhibitors, including the selective Janus kinase inhibitor upadacitinib, in many inflammatory diseases, including atopic dermatitis, there remains a need to accumulate real-world clinical data, especially in patients with refractory atopic dermatitis and comorbid conditions. Aim — to evaluate the long-term efficacy, safety, and dynamics of potential biomarkers during upadacitinib therapy in patients with severe atopic dermatitis and comorbid pathology. This case series presents data from 5 adult patients (3 men, 2 women) with severe atopic dermatitis refractory to standard therapy. All patients received upadacitinib 30 mg once daily for 52 weeks. Efficacy was assessed by dynamics in Scoring Atopic Dermatitis Index, Eczema Area and Severity Index, Investigator’s Global Assessment scores, Numerical Rating Scale; Dermatology Life Quality Index. Safety was evaluated through monitoring of adverse events. Gene expression of cytokines (TARC/CCL17, MDC/CCL22, PARC/CCL18, CTACK/CCL27, eotaxin-3/CCL26, interleukins 4, 13, 17, 22, 25, 33, thymic stromal lymphopoietin) was analyzed using real-time polymerase chain reaction at baseline and at week 16 of therapy. Control over atopic dermatitis symptoms was achieved in all patients: by week 40, 100 % (5/5) of patients had achieved an Eczema Area and Severity Index 90 response, which was maintained until the end of the 52-week observation period. The median Scoring Atopic Dermatitis Index decreased from 65.3 to 2.6 by week 40, and the median Eczema Area and Severity Index score decreased from 47.6 to 0.7 by week 28. Numerical Rating Scale score decreased from 5 to 1 (median) by week 16. During the observation period, 26 mild adverse events were recorded; no serious adverse events were reported. Complete drug-induced remission was observed in one female patient with comorbid alopecia areata. No statistically significant changes were detected in the profile of the studied biomarkers. In this case series, upadacitinib demonstrated high efficacy and a favorable safety profile in patients with severe refractory atopic dermatitis over 52 weeks of therapy. The observed remission of comorbid alopecia areata expands understanding of the drug’s therapeutic potential. Larger prospective studies are needed to confirm these findings and to identify predictive biomarkers.

Zitieren

APA

Smolnikov, E. V., Byazrova, M. G., Litovkina, A. O., Elisyutina, O. G., & Fedenko, E. S. (2026). Clinical efficacy and potential biomarkers of response to upadacitinib therapy in patients with severe atopic dermatitis and comorbidities. Russian Journal of Allergy, 23(2), 247-257. https://doi.org/10.36691/rja17090

Vancouver

Smolnikov EV, Byazrova MG, Litovkina AO, Elisyutina OG, Fedenko ES. Clinical efficacy and potential biomarkers of response to upadacitinib therapy in patients with severe atopic dermatitis and comorbidities. Russian Journal of Allergy. 2026;23(2):247-257. doi:10.36691/rja17090

BibTeX
@article{Smolnikov2026,
  author = {Smolnikov, Evgeniy V. and Byazrova, Maria G. and Litovkina, Alla O. and Elisyutina, Olga G. and Fedenko, Elena S.},
  title = {Clinical efficacy and potential biomarkers of response to upadacitinib therapy in patients with severe atopic dermatitis and comorbidities},
  journal = {Russian Journal of Allergy},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {247--257},
  doi = {10.36691/rja17090}
}
Kostenlos starten →